{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:10:04Z","timestamp":1790770204721,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.pharma.2020.01.005","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T11:12:21Z","timestamp":1579777941000},"page":"343-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Exposition des nouveau-n\u00e9s aux parab\u00e8nes via les m\u00e9dicaments administr\u00e9s durant leur hospitalisation"],"prefix":"10.1016","volume":"78","author":[{"given":"G.","family":"Binson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cariot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Venisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rabouan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Beuzit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2020.01.005_bib0200","series-title":"Global status report on noncommunicable diseases","first-page":"2011","author":"World Health Organization","year":"2010"},{"issue":"5","key":"10.1016\/j.pharma.2020.01.005_bib0205","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2796.2007.01809.x","article-title":"The origins of the developmental origins theory","volume":"261","author":"Barker","year":"2007","journal-title":"J Intern Med"},{"issue":"05","key":"10.1016\/j.pharma.2020.01.005_bib0210","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1017\/S2040174415001129","article-title":"The birth and future health of DOHaD","volume":"6","author":"Hanson","year":"2015","journal-title":"J Dev Orig Health Dis"},{"issue":"1","key":"10.1016\/j.pharma.2020.01.005_bib0215","first-page":"42","article-title":"Developmental origins of non-communicable disease: implications for research and public health","volume":"11","author":"Barouki","year":"2012","journal-title":"Environ Health Glob Access Sci Source"},{"key":"10.1016\/j.pharma.2020.01.005_bib0220","first-page":"S3","volume":"211","author":"Bergman","year":"2012"},{"key":"10.1016\/j.pharma.2020.01.005_bib0225","series-title":"Commission et . Regulation (EU) 2018\/605\u00a0of 19\u00a0April 2018\u00a0amending Annex II to Regulation (EC) No 1107\/2009\u00a0by setting out scientific criteria for the determination of endocrine disrupting properties (Text with EEA relevance.) [Internet]","year":"2018"},{"issue":"4","key":"10.1016\/j.pharma.2020.01.005_bib0230","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1210\/er.2009-0002","article-title":"Endocrine-disrupting chemicals: an endocrine society scientific statement","volume":"30","author":"Diamanti-Kandarakis","year":"2009","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharma.2020.01.005_bib0235","series-title":"State of the art assessment of endocrine disrupters","author":"Kortenkamp","year":"2011"},{"key":"10.1016\/j.pharma.2020.01.005_bib0240","first-page":"379","volume":"2\/2012","author":"European Environment Agency","year":"2012"},{"key":"10.1016\/j.pharma.2020.01.005_bib0245","series-title":"Endocrine disrupters. Possible developmental early effects of endocrine disrupters on child health possible developmental early effects of endocrine disrupters on child health","author":"WHO","year":"2012"},{"issue":"10","key":"10.1016\/j.pharma.2020.01.005_bib0250","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1210\/jc.2011-1269","article-title":"The exposure of fetuses and children to endocrine disrupting chemicals: a European Society for Paediatric Endocrinology (ESPE) and Pediatric Endocrine Society (PES) call to action statement","volume":"96","author":"Skakkebaek","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharma.2020.01.005_bib0255","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.mce.2018.03.014","article-title":"Parabens and their effects on the endocrine system","volume":"474","author":"Nowak","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharma.2020.01.005_bib0260","series-title":"Expertise collective-reproduction et environnement","first-page":"89","author":"INSERM","year":"2011"},{"issue":"1","key":"10.1016\/j.pharma.2020.01.005_bib0265","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jat.958","article-title":"Concentrations of parabens in human breast tumours","volume":"24","author":"Darbre","year":"2004","journal-title":"J Appl Toxicol"},{"issue":"5","key":"10.1016\/j.pharma.2020.01.005_bib0270","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/jat.1358","article-title":"Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks","volume":"28","author":"Darbre","year":"2008","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.pharma.2020.01.005_bib0275","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.envres.2016.07.011","article-title":"Human exposure to endocrine disrupting compounds: their role in reproductive systems, metabolic syndrome and breast cancer. A review","volume":"151","author":"Giulivo","year":"2016","journal-title":"Environ Res"},{"issue":"1","key":"10.1016\/j.pharma.2020.01.005_bib0280","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/humrep\/dey337","article-title":"Association of phthalates, parabens and phenols found in personal care products with pubertal timing in girls and boys","volume":"34","author":"Harley","year":"2019","journal-title":"Hum Reprod"},{"key":"10.1016\/j.pharma.2020.01.005_bib0285","series-title":"Rapport au Parlement relatif aux pertubateurs endocriniens.","year":"2014"},{"key":"10.1016\/j.pharma.2020.01.005_bib0290","series-title":"Reflection paper on the use of methyl-and propylparaben as excipients in human medicinal products for oral use","author":"European Medicine Agency","year":"2013"},{"key":"10.1016\/j.pharma.2020.01.005_bib0295","volume":"27","author":"Acad\u00e9mie Nationale de Pharmacie","year":"2013"},{"issue":"12","key":"10.1016\/j.pharma.2020.01.005_bib0300","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology \u2014 drug disposition, action, and therapy in infants and children","volume":"349","author":"Wood","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pharma.2020.01.005_bib0305","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/jps.2600720919","article-title":"Urinary excretion of methylparaben and its metabolites in preterm infants","volume":"72","author":"Hindmarsh","year":"1983","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.pharma.2020.01.005_bib0310","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1289\/ehp.0800265","article-title":"Exposure to bisphenol A and other phenols in neonatal intensive care unit premature infants","volume":"117","author":"Calafat","year":"2009","journal-title":"Environ Health Perspect"},{"issue":"3","key":"10.1016\/j.pharma.2020.01.005_bib0315","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s11095-014-1520-2","article-title":"An observational study of blood concentrations and kinetics of methyl- and propyl-parabens in neonates","volume":"32","author":"Mulla","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharma.2020.01.005_bib0320","series-title":"Guide m\u00e9thodologique des \u00e9tudes de stabilit\u00e9 des pr\u00e9parations","author":"Sautou","year":"2013"},{"key":"10.1016\/j.pharma.2020.01.005_bib0325","series-title":"Microbiological quality of non-sterile products for pharmaceutical use. 2(v01)","first-page":"507","author":"European Pharmacopoeia","year":"2011"},{"issue":"4","key":"10.1016\/j.pharma.2020.01.005_bib0330","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/pharmaceutics11040190","article-title":"Preparation and physicochemical stability of liquid oral dosage forms free of potentially harmful excipient designed for pediatric patients","volume":"11","author":"Binson","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.pharma.2020.01.005_bib0335","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1186\/1471-2431-12-136","article-title":"Hospitalised neonates in Estonia commonly receive potentially harmful excipients","volume":"12","author":"Lass","year":"2012","journal-title":"BMC Pediatr"},{"issue":"7","key":"10.1016\/j.pharma.2020.01.005_bib0340","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00431-014-2272-z","article-title":"Toxic excipients in medications for neonates in Brazil","volume":"173","author":"Souza","year":"2014","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.pharma.2020.01.005_bib0345","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11096-016-0277-6","article-title":"Harmful excipients in medicines for neonates in Spain","volume":"38","author":"Garcia-Palop","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"10.1016\/j.pharma.2020.01.005_bib0350","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/archdischild-2014-307793","article-title":"Potentially harmful excipients in neonatal medicines: a pan-European observational study","volume":"100","author":"Nellis","year":"2015","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.pharma.2020.01.005_bib0355","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/jes.2010.6","article-title":"Andersson A-M. Parabens in urine, serum and seminal plasma from healthy Danish men determined by liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS)","volume":"21","author":"Frederiksen","year":"2011","journal-title":"J Expo Sci Environ Epidemiol"},{"key":"10.1016\/j.pharma.2020.01.005_bib0360","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.envint.2015.08.012","article-title":"Maternal and fetal exposure to parabens in a multiethnic urban U.S. population","volume":"84","author":"Pycke","year":"2015","journal-title":"Environ Int"},{"key":"10.1016\/j.pharma.2020.01.005_bib0365","doi-asserted-by":"crossref","first-page":"104917","DOI":"10.1016\/j.envint.2019.104917","article-title":"Pharmacokinetic profile of propyl paraben in humans after oral administration","volume":"130","author":"Shin","year":"2019","journal-title":"Environ Int"},{"key":"10.1016\/j.pharma.2020.01.005_bib0370","series-title":"R\u00e8glement (UE) no\u00a01004\/2014\u00a0de la Commission du 18\u00a0septembre 2014\u00a0modifiant l\u2019annexe V du r\u00e8glement (CE) no\u00a01223\/2009\u00a0du Parlement europ\u00e9en et du Conseil relatif aux produits cosm\u00e9tiques Texte pr\u00e9sentant de l\u2019int\u00e9r\u00eat pour l\u2019EEE [Internet]","author":"Commission europ\u00e9enne","year":"2014"},{"key":"10.1016\/j.pharma.2020.01.005_bib0375","unstructured":"Code de la sant\u00e9 publique - article L5131-1. Code de la sant\u00e9 publique."},{"key":"10.1016\/j.pharma.2020.01.005_bib0380","unstructured":"Scientific Committee on Consumer Products (SCCP). Extended opinion on the safety evaluation of parabens."},{"issue":"2","key":"10.1016\/j.pharma.2020.01.005_bib0385","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.reprotox.2010.03.011","article-title":"Possible endocrine disrupting effects of parabens and their metabolites","volume":"30","author":"Boberg","year":"2010","journal-title":"Reprod Toxicol"},{"issue":"3","key":"10.1016\/j.pharma.2020.01.005_bib0195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.yrtph.2009.08.004","article-title":"Refining aggregate exposure: example using parabens","volume":"55","author":"Cowan-Ellsberry","year":"2009","journal-title":"Regul Toxicol Pharmacol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450920300055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450920300055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:34:21Z","timestamp":1757720061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450920300055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0003450920300055"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2020.01.005","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exposition des nouveau-n\u00e9s aux parab\u00e8nes via les m\u00e9dicaments administr\u00e9s durant leur hospitalisation","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2020.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}